Skip to Main Content

Paper Details

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
Clin Cancer Res
40
2016
BRAF, BRAF-Mutant Melanoma, BRAF-mutant, BRAF-mutant melanoma cell lines, CDX-011, Cancer, GPNMB, MAPK, MEK, MITF, melanoma, melanoma cells, melanomas, melanosomal differentiation genes, patients
Author NameAffiliation
Lawrence N KwongThe University of Texas MD Anderson Cancer Center
Lynda ChinThe University of Texas MD Anderson Cancer Center
Lynda ChinInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center
Ian R WatsonGoodman Cancer Research Centre, McGill University
Ian R WatsonMcGill University
  • 1 - 5

Datasets

Release 1.2